"Occasional" Is the Word Holding Heartburn Copy Up

what exactly did fda say about occasional versus recurrent heartburn?

FDA settled this question in the preamble to its 2000 structure/function rulemaking, and it did so in exact language rather than general guidance. The agency wrote that “‘relief of heartburn’ and ‘relief of acid indigestion’ without further qualification are not appropriate structure/function claims,” closing off the plain, unqualified sales pitch entirely.

Add the word ‘occasional’ and the same sentence survives review. FDA accepts ‘occasional heartburn’ and ‘occasional acid indigestion’ as usable structure/function language, on the reasoning that a stomach acting up once in a while is not, by itself, evidence of an underlying disease process.

Frequency is the whole test, and FDA said so in the same passage: “‘recurrent’ or ‘persistent’ heartburn and acid indigestion can be hallmarks of significant illness, and are therefore disease claims.” That illness is gastroesophageal reflux disease, and copy describing heartburn as constant, nightly or ongoing describes GERD without naming it. The same single-word test decides a different symptom entirely in occasional or chronic: the word that decides.

why are "sour stomach" and "upset stomach" treated differently?

We could not verify this distinction from a primary FDA source, and that gap deserves naming rather than a confident guess. FDA’s 2000 preamble addresses ‘heartburn’ and ‘acid indigestion’ by name; nothing in the material we reviewed extends the same occasional-versus-recurrent test explicitly to ‘sour stomach’ or ‘upset stomach.’

What would settle it is a warning letter or FDA guidance document quoting either phrase directly, the way the rule text quotes heartburn.

The safer assumption follows the same logic anyway. Any phrase that also functions as an approved indication for an over-the-counter antacid drug risks the same “class of products” trigger the rule applies elsewhere, so treat ‘sour stomach’ and ‘upset stomach’ with the same occasional-qualifier discipline you’d use for heartburn until a primary source says otherwise.

what happens when permitted and prohibited terms share one indications list?

The permitted word stops providing cover once it sits inside a list of disease indications. FDA reads labeling as a whole rather than grading each word in isolation, and a warning letter to a supplement seller in November 2025 shows exactly how that works.

The agency’s warning letter to 123Herbals, issued November 13, 2025, cites label copy for a product called BOON ANTACID that reads: “‘BOON ANTACID herbals For Use: Gastric pain, Dyspepsia, Bloating, Flatulence, Heartburn, Indigestion.’” We checked the label FDA quoted directly, and heartburn sits fourth in that six-item list, positioned between other lay symptom terms rather than isolated on its own. FDA’s letter treats the entire indications block as a single unit of evidence for drug intent, not six words to be scored individually, which means inserting ‘occasional’ in front of heartburn would not have rescued this label even if someone had tried, because the list itself — independent of any one term inside it — is what converts the product into an unapproved new drug.

Context beats vocabulary every time.

why did the word "antacid" in a product name draw a citation?

The name itself functioned as the disease claim, independent of anything the body copy said. 21 CFR 101.93(g)(2)(iv)(A) lists a product’s own name as one of the enumerated ways labeling can convey disease treatment, and ‘antacid’ names a category of over-the-counter drug rather than a dietary supplement function.

FDA applied the identical naming logic to a different niche in the same rulemaking. A supplement could be called HeartTabs only if a maintenance claim about circulation sat right beside the name — an unqualified organ or drug-class word in a product title works as its own implied disease claim, with or without a single sentence of supporting copy.

BOON ANTACID had no such qualifier attached to the name. Nothing beside it narrowed the product to occasional relief, and the name sat directly above a six-item list of gastrointestinal conditions — a combination FDA treated as drug intent before reaching a single line of body copy.

does gerd ever have a compliant structure/function framing?

No — GERD is named as a disease, and a structure/function claim cannot reference a named disease under any framing FDA has published. The agency’s list of twelve health claims meeting the significant scientific agreement standard runs from calcium and osteoporosis to sodium and hypertension, and none of them touch gastroesophageal reflux, heartburn frequency, or any other digestive disease.

There is also no qualified health claim covering GERD — the intermediate route FDA has used for endpoints like blood pressure through letters of enforcement discretion. That route does not exist here, so structure/function isn’t the preferred path for a heartburn offer. It’s the only path available, and it tops out at occasional symptoms.

The same conditional pattern shows up one digestive symptom over, where occasional constipation is allowed, with a condition rather than banned outright — heartburn just clears the bar at a stricter frequency word.

The ceiling sits at occasional, and nothing sits above it.

how do lay-language symptom lists get caught by 101.93(g)(2)(ii)?

21 CFR 101.93(g)(2)(ii) catches symptom lists because it names lay terminology explicitly, not only clinical vocabulary. The rule converts a statement into a disease claim if it describes an effect on the “characteristic signs or symptoms” of a disease, whether the label uses scientific or lay terminology — so “stomach acting up all the time” reads the same as “GERD” to FDA.

FTC applies the identical instinct from a separate statute, and its own guidance spells out why plain description is enough on its own. In an unrelated cold-remedy example the agency wrote that “Even without the product name and images, the reference to nose and throat health during the winter season likely conveys a cold prevention claim,” per the FTC Health Products Compliance Guidance. The same reasoning applies to a heartburn page that lists gastric pain and dyspepsia next to it without naming GERD anywhere.

The distinction below is the one to keep in front of whoever writes the landing page.

what wording change fixes a heartburn landing page without killing the angle?

The fix is narrower than most advertisers expect: change the frequency word and the indications list, not the whole angle. Replace “relief of heartburn” with “relief of occasional heartburn” everywhere it appears on your page, replace any list of gastrointestinal conditions with one structure/function statement, and drop “antacid” from the product name and headline alike.

The same single-word test decided a different vertical already, in ‘occasional’ is the word holding up energy offers, and it decides your heartburn page the same way.

None of this touches your ingredient or your price.

• Add “occasional” immediately before heartburn and acid indigestion — headline, meta description, and landing page body, every time either term appears.
• Delete any indications list pairing heartburn with dyspepsia, gastric pain, bloating, or flatulence; each is a separate lay symptom term under 21 CFR 101.93(g)(2)(ii).
• Rename away from antacid or any other OTC drug-category word, and carry the change through your domain and packaging, not just the ad copy.
• Keep the required 101.93(c) disclaimer, but don’t lean on it — we checked the rule text, and the disclaimer only accompanies a lawful claim; it doesn’t convert an unlawful one.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Peptides vs. DSHEA: Why Most Peptides Can Never Be Supplements, Why 'Research Use Only' Is Not a Legal Shield for Peptide Sellers, Compounded GLP-1 in 2026: What's Still Legal Now That the Shortage Is Over, 'Nature's Ozempic': Where Berberine Marketing Crosses the Legal Line, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.